$16.35 0.09 (+0.55%)
11/20/2009 4:00 PM

XenoPort, Inc. (XNPT)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transporter mechanisms to improve the therapeutic benefits of drugs.

Current Price $16.35 Mkt Cap $496.06M
Open $16.15 P/E Ratio 47.05
Prev. Close $16.26 Div. (Yield) N/A (N/A)
Daily Range $16.00 - $16.47 Volume 424,401
52-Wk Range $13.36 - $32.93 Avg. Daily Vol. 404,000

XNPT News and Commentary

Related News and Articles

Caps

How do you think XNPT will perform vs the S&P 500?

Add Stock to Watchlist

All Members

72 Outperform
28 Underperform
 

All-Star Members

11 Outperform
9 Underperform
 

Wall Street

11 Outperform
0 Underperform
 

Top XNPT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

majakblue (< 20)
Submitted April 26, 2007

They have a product in phase III trials. Stock will keep going up until product goes kapluuie or executives start buying castles. Pull out of this one if there is a negative report on the product!

0 Comments | Reply | Report this Post

goldminingXpert (99.97)
Submitted November 07, 2008

zeroport? As in, zero $ left in your portfolio? Truth in advertising!

0 Comments | Reply | Report this Post
XNPT VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about XNPT.

Recs

0
Member Avatar EclecticRecluse (75.31) Submitted: 11/17/2009 4:54:47 AM : Underperform Start Price: $15.96 XNPT Score: -3.79

Negative Earnings Surprise

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar AndrewGreenBull (98.06) Submitted: 11/16/2009 10:26:23 AM : Outperform Start Price: $17.47 XNPT Score: -6.44

2/09/2010

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar Alex1963 (97.84) Submitted: 9/17/2009 1:18:45 PM : Outperform Start Price: $24.50 XNPT Score: -36.24

from article in Morn* 9/17/09
announced positive results Thursday from a Phase IIb clinical trial for XP13512 for neuropathic pain associated with post-herpetic neuralgia. The drug candidate was successful in demonstrating statistically significant results over placebo at all dosing levels, and we plan to slightly raise our fair value estimate in the wake of this news. The 14-week, double-blind trial evaluated the safety and efficacy of XP13512 and had a total enrollment of 375 subjects with PHN who experienced pain following the healing of the herpes zoster (shingles) skin rash for at least three months. XP13512 was statistically significan t on the primary endpoint of the trial, which was improvement from baseline in the 24-hour average pain intensity score. We think this is great news for XenoPort, which experienced a setback with XP13512 in April, when the drug failed a Phase II study for pain associated with diabetes. XenoPort has partnered with GlaxoSmithKline GSK on the drug, which is still on track for final approval from the Food and Drug Administration for restless leg syndrome, having met all primary goals in its Phase III trials.

Report this Post 0 Comments | Reply | Permalink
View All 13 Pitches »

Leaderboard

Find the members with the highest scoring picks in XNPT.

Score Leader

Drmomski

Drmomski (63.14) Score: +80.77

The Score Leader is the member with the highest score across all their picks in XNPT.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
Drmomski 63.14 11/17/2008 Underperform 1Y $33.12 -50.63% +30.13% +80.77
SidBord < 20 11/11/2008 Underperform 3Y $34.14 -52.11% +23.58% +75.69
thegraveyard < 20 2/24/2009 Underperform NS $22.53 -27.43% +47.12% +74.55
pdxlucky 67.30 10/14/2008 Underperform 5Y $40.93 -60.05% +13.71% +73.76
qubit15 25.05 1/21/2009 Underperform NS $24.97 -34.52% +36.73% +71.25
Evad005 59.11 3/25/2009 Underperform 3M $21.07 -22.40% +35.97% +58.37
RenwayGlobal 75.43 3/27/2009 Underperform 5Y $20.90 -21.77% +34.71% +56.48
mukwonago53149 78.08 1/17/2008 Underperform 3Y $61.40 -73.37% -17.24% +56.13 1 Comment
drakitin 99.48 8/15/2008 Underperform 1Y $50.59 -67.68% -13.24% +54.44
APGalatia 93.79 8/12/2008 Underperform 1Y $46.47 -64.82% -12.48% +52.34
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackLadenburg 36.87 6/11/2009 Outperform NS $21.66 -24.52% +16.91% -41.42
TrackMaximGroup < 20 4/28/2009 Outperform NS $14.78 +10.62% +28.88% -18.26
TrackWedbush < 20 3/20/2009 Outperform NS $19.76 -17.26% +42.61% -59.87
TrackHapoalim 45.06 2/19/2009 Outperform NS $26.02 -37.16% +39.61% -76.77
TrackPiperJaff 78.45 12/16/2008 Outperform NS $20.23 -19.18% +27.14% -46.32
TrackCreditSuiss 90.95 12/15/2008 Outperform NS $20.37 +25.38% -6.46% +31.84 2/13/2009 @ $25.54
TrackRodmanRen < 20 12/2/2008 Outperform NS $18.60 -12.10% +32.16% -44.26
TrackLazardCapit < 20 9/23/2008 Outperform NS $45.52 -67.75% -28.09% -39.66 4/27/2009 @ $14.68
TrackFBRCapitalM 73.72 7/9/2008 Outperform NS $39.35 -4.75% -1.73% -3.03 7/10/2008 @ $37.48
TrackLadenburg 36.87 5/8/2008 Outperform NS $40.00 -62.02% -36.94% -25.09 4/27/2009 @ $15.19
TrackRWBaird 81.68 4/3/2008 Outperform NS $42.92 -61.91% -16.56% -45.35
TrackRBCCapMkts 82.07 1/16/2008 Outperform NS $61.30 -73.33% -17.08% -56.24
TrackCowenandCo 69.87 9/4/2007 Outperform NS $41.43 -60.54% -21.88% -38.66
TrackCitigroup < 20 8/9/2007 Outperform NS $42.63 -57.78% -43.04% -14.74 12/3/2008 @ $18.00
TrackDeutscheSec 87.23 4/26/2007 Outperform NS $44.64 -63.37% -22.59% -40.79
TrackFBRCapitalM 73.72 4/11/2007 Outperform NS $29.27 +72.53% +2.08% +70.45 12/3/2007 @ $50.50
TrackPZK < 20 1/17/2007 Outperform NS $24.94 -34.44% -18.69% -15.75
TrackLazardCapit < 20 8/11/2006 Outperform NS $17.82 +132.77% +16.57% +116.20 8/9/2007 @ $41.48

Featured Broker Partners